Afamelanotide mastery course
Unit 10 of 12
How the implant is administered
Afamelanotide is given as a 16 mg controlled-release implant placed under the skin by a clinician, every two months,…
The approved protocol, and what gray-market use is not
Afamelanotide is given as a 16 mg controlled-release implant placed under the skin by a clinician, every two months, and since September 2025 the European label allows that year-round rather than capping it at four implants a year. This unit explains that approved protocol and the pharmacokinetic logic behind it.
It then clearly separates what the gray-market does, reconstituting and injecting powder, as something reported, not endorsed. This is education only, not a protocol, and afamelanotide is clinician-administered by design.